drugset / Trial / NCT04107961
A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)
Phase 2
Withdrawn
University of York
European Vaccine Initiative · collabEuropean and Developing Countries Clinical Trials Partnership (EDCTP) · collabWellcome Trust · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The actual format of the anticipated LEISH3 trial is under review.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2024-12
- Completion
- 2025-07
Outcome
Outcome not reported
Stopped: “The trial will be undertaken but the protocol will be substantially revised.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ChAd63-KH | Vaccine | 1 ml | Intramuscular |